Jorey Chernett, identified as a ten percent owner of Neuronetics, Inc. (NASDAQ: STIM), reported buying 169,472 shares of the company on March 20, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The filings show the purchases occurred across multiple transactions at prices that ranged from $1.36 to $1.44 per share and settled at a weighted average purchase price of $1.41, yielding a cumulative transaction value of $238,955.
Following the March 20 transaction, Chernett's direct ownership in Neuronetics stands at 8,743,276 shares. At the time the filing was noted, the company's stock price was trading at $1.59. The share price has declined 70% over the previous 12 months while recording a 6.6% advance in the most recent month.
Analysis drawn from InvestingPro is cited in the filing summary, indicating that Neuronetics appears overvalued relative to its Fair Value estimate. The platform also flagged a rapid cash burn at the company as one of multiple ProTips available to subscribers. The same platform offers a deeper Pro Research Report covering Neuronetics among more than 1,400 U.S. equities for subscribers who want extended analysis.
Operational and market developments for Neuronetics in recent disclosures present a mixed picture. The company reported fourth-quarter 2025 revenue of $41.8 million, exceeding the forecasted $40.66 million and producing a 2.73% positive surprise on the top line. However, earnings per share came in at negative $0.10, short of the expected negative $0.09 and representing an 11.11% negative surprise on EPS.
On the analyst front, Canaccord lowered its price target for Neuronetics from $7.00 to $3.00 while maintaining a Buy rating. The firm commented that the company's fourth-quarter results and guidance were in line with expectations. Separately, Neuronetics announced Dan Reuvers as its new chief executive officer and reported that it was operationally cash flow positive in the second quarter.
The insider purchase by Chernett increases that individual investor's exposure to Neuronetics as the company works through near-term financial dynamics reflected in results, guidance and analyst adjustments. The filings and accompanying third-party commentary provide investors with discrete datapoints on ownership changes, recent operating performance and analyst posture without drawing further conclusions beyond the disclosed facts.